SCHEMBL1704736

SCHEMBL1704736

Cc1nc(NC(=O)c2cccc(Cl)c2)sc1C(=O)Nc1cccnc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.62
MEN1 O00255 7/20 0.60
KMT2A Q03164 7/20 0.60
POLB P06746 1/20 0.60
MAPT P10636 5/20 0.59
ALDH1A1 P00352 3/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
KDM4E B2RXH2 2/20 0.59
HSP90AA1 P07900 1/20 0.59
CSF1R P07333 1/20 0.59
CLK1 P49759 1/20 0.57
TP53 P04637 1/20 0.55
HPGD P15428 1/20 0.55
NPC1 O15118 2/20 0.54
GRM5 P41594 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
LCK P06239 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3588764 0.84 MAPT (0.76) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL3581760 0.84 NAMPT (0.70) KMT2APOLBMAPTALDH1A1KDM4E
SCHEMBL27706884 0.82 KMT2A (0.66) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL4200739 0.81 MEN1 (0.69) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL3589868 0.81 RAB9A (0.72) BRAFMEN1KMT2APOLBMAPT
SCHEMBL27706885 0.81 TP53 (0.51) BRAFMEN1KMT2APOLBMAPT
SCHEMBL1276903 0.77 BRAF (1.00) BRAFMEN1KMT2ACSF1R
SCHEMBL3580760 0.76 SCD (0.65) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL3590314 0.76 RAB9A (0.75) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL774978 0.76 LCK (0.78) TP53LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541457-B2 Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors XENON PHARMACEUTICALS INC. (CA) 2013-09-24 US claimed
US-20130096056-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2013-04-18 US claimed
EP-2540296-A1 Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors Xenon Pharmaceuticals Inc. (CA) 2013-01-02 EP claimed
US-20100152187-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2010-06-17 US claimed
EP-2029138-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2009-03-04 EP claimed
WO-2007130075-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2007-11-15 WO claimed
EP-2960341-B1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE MOLECULAR HEALTH GMBH (DE) 2018-06-27 EP disclosed
EP-3263717-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE Molecular Health GmbH (DE) 2018-01-03 EP disclosed
US-20170315128-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE MOLECULAR HEALTH GMBH (DE) 2017-11-02 US disclosed
EP-2435581-B1 METHODS OF USE OF A NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) MOLECULAR HEALTH GMBH (DE) 2017-07-26 EP disclosed
EP-2960341-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE Molecular Health GmbH (DE) 2015-12-30 EP disclosed
EP-2492355-B1 Tissue protective erythropoietin receptor (nepor) and methods of use MOLECULAR HEALTH GMBH (DE) 2015-04-08 EP disclosed
US-20140296318-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE MOLECULAR HEALTH GMBH (DE) 2014-10-02 US disclosed
WO-2010136192-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE ALEPOR GMBH & CO. KG (DE) 2010-12-02 WO disclosed
US-20100152187-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2010-06-17 US disclosed
US-20090306186-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE ALEPOR GMBH & CO. KG 2009-12-10 US disclosed
EP-2109690-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE Alepor GMBH & CO. KG (DE) 2009-10-21 EP disclosed
WO-2009068677-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE ALEPOR GMBH & CO. KG (DE) 2009-06-04 WO disclosed
EP-2029138-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2009-03-04 EP disclosed
WO-2007130075-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152187-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS SCD, SCD5, ACAT1 BRAF 4827/4885MEN1 4846/4885KMT2A 1897/4885
US-20130096056-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS SCD, SCD5, ACAT1 BRAF 4829/4885MEN1 4846/4885KMT2A 1901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.